Carta de PA para Horizon Blue Cross Blue Shield of New Jersey: SOP con síndrome metabólico.

La carta (copiar y editar)

Copie el cuerpo a continuación y péguelo en el portal de su clínico o procesador de textos. Reemplace cada marcador de posición entre [CORCHETES] con datos específicos del paciente antes de enviar. La carta es de su clínico al plan, firmada por su clínico.

[Today's date]

Horizon Blue Cross Blue Shield of New Jersey
Prior Authorization Department
Submitted via: NaviNet provider portal or fax 1-800-682-9510

Re: Prior Authorization Request, Wegovy, Zepbound or off-label Mounjaro depending on T2D status
Patient: [Patient full name]
Member ID: [Plan member ID]
Date of birth: [Patient DOB]
Group number: [Group number if applicable]
Prescriber: [Prescriber full name, NPI, DEA]
Prescriber contact: [Phone, fax, email]

To the Horizon Blue Cross Blue Shield of New Jersey Prior Authorization Reviewer,

I am the treating clinician for [Patient name]. I am writing to request prior authorization for Wegovy, Zepbound or off-label Mounjaro depending on T2D status for treatment of PCOS with metabolic syndrome (ICD-10: E28.2, E66.9, R73.03).

Clinical justification

PCOS itself is not an FDA-approved indication for any GLP-1 receptor agonist, but PCOS frequently coexists with insulin resistance, prediabetes and obesity, each of which is a qualifying indication. This PA pathway requests coverage under the obesity indication (if BMI greater than or equal to 30 or 27 with comorbidity) or under the T2D indication (if A1c greater than or equal to 6.5 percent). PCOS-specific evidence: a 2023 systematic review in Reproductive Sciences pooled GLP-1 trial data in women with PCOS and found significant improvements in BMI, insulin resistance (HOMA-IR) and androgen levels at 12 to 24 weeks of treatment.

Patient-specific findings

  - [Insert current measurements: weight, height, BMI, blood pressure]
  - [Insert relevant lab values with dates: A1c, lipid panel, kidney function]
  - [Insert documentation of comorbidities with ICD-10]
  - [Insert documentation of prior treatment history, including any prior GLP-1 trials, anti-obesity medication trials or lifestyle intervention]

Criteria met per Horizon Blue Cross Blue Shield of New Jersey policy

This request meets the criteria set out in Horizon BCBSNJ Medical Policy 117, Anti-Obesity Pharmacotherapy:

  - PCOS diagnosis documented with ICD-10 E28.2 (often confirmed by Rotterdam criteria)
  - Documentation of metabolic complications: insulin resistance, prediabetes (A1c 5.7 to 6.4) or T2D (A1c greater than or equal to 6.5)
  - BMI documented (qualifies under obesity pathway if 30 or above, or 27 with comorbidity)
  - Six-month lifestyle intervention documented for the obesity pathway
  - Endocrinology or reproductive endocrinology consult letter (strengthens but not always required)

Supporting evidence

The clinical case for Wegovy, Zepbound or off-label Mounjaro depending on T2D status in this indication is supported by the following registration trials and outcomes data:

  - Jensterle et al. 2014 (liraglutide in PCOS, Endocrine Connections)
  - Frossing et al. 2018 (liraglutide in PCOS, Diabetes Obesity and Metabolism)
  - Pooled meta-analyses of GLP-1 in PCOS (Reproductive Sciences 2023)

Plan-specific note

Horizon BCBS covers Wegovy and Zepbound at BMI greater than or equal to 30 (or 27 with weight-related comorbidity). Six months of lifestyle intervention required. Prime Therapeutics is the PBM for most Horizon commercial lines. Horizon NJ Health (Medicaid managed care) follows the New Jersey FamilyCare PDL, which has historically excluded GLP-1 for obesity indication; route T2D or CV indication for Medicaid members. Verify your specific plan's policy.

Requested action

I am requesting prior authorization for Wegovy, Zepbound or off-label Mounjaro depending on T2D status at the [insert starting dose] starting dose, with planned titration per FDA labeling. I am also requesting that this authorization be granted for a continuous 12-month period subject to documented clinical response, per standard formulary practice.

If additional information is required, please contact me directly at [Prescriber phone] or [Prescriber email]. I am available to discuss this case with your medical director if helpful.

Thank you for your attention to this request.

Sincerely,

[Prescriber full signature]
[Prescriber printed name, credentials]
[Prescriber NPI]
[Practice name and address]

Attachments:
  - Current vital signs and BMI calculation
  - Most recent relevant labs
  - Documentation of comorbidities
  - Documentation of prior treatment trials
  - Sleep study report (if OSA indication)
  - Cardiac history documentation (if CV indication)

Aviso legal

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact